Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Stoke Therapeutics, Inc.’s Chief Medical Officer, Barry Ticho, reported an option exercise and related share sales. He exercised a stock option for 1,365 shares of common stock at $2.19 per share and then sold a total of 14,311 shares in open-market transactions at prices between $29.99 and $33.855 per share.
The filing notes that part of the activity was an issuer-mandated sale to cover tax withholding tied to restricted stock unit vesting, and that transactions were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025. Following these transactions, Ticho directly holds 40,702 shares of Stoke Therapeutics common stock, with the reported option now fully vested and exercisable.
Stoke Therapeutics, Inc. Chief Financial Officer Thomas Leggett reported issuer-mandated sales of 4,578 shares of common stock on March 17–18, 2026 to satisfy tax withholding obligations tied to vesting of restricted stock units. The shares were sold in multiple open-market transactions at weighted-average prices generally in the low‑$30s, with individual trades ranging from $30.59 to $33.855 per share. Following these transactions, he directly holds 10,172 shares of Stoke Therapeutics common stock, indicating the activity was a tax-related disposition rather than a complete exit from his equity position.
Stoke Therapeutics Chief Patient Officer Jason Hoitt reported mandated share sales to cover taxes on vested stock units. On March 17–18, 2026, he sold a total of 3,712 shares of common stock in open-market transactions required to satisfy tax withholding obligations. Sale prices were based on weighted averages, with individual trades occurring in ranges between $30.59 and $33.855 per share. After these transactions, he directly holds 10,276 shares, and no remaining stock options or other derivatives are reported.
Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported open‑market sales of 8,895 shares of common stock in multiple transactions on March 17–18. A footnote states these sales were issuer‑mandated to satisfy tax withholding liabilities from vesting restricted stock units. After the transactions, he holds 28,836 shares of common stock directly.
Morgan Stanley Smith Barney LLC lists proposed sales of Common shares in a Form 144 notice. The filing shows a proposed sale tied to an exercise of stock options dated 03/19/2026 for 1,365 shares and restricted stock units dated 12/01/2025 for 96 shares.
Stoke Therapeutics, Inc. filed a shelf registration and prospectus to offer $150,000,000 of common stock for sale from time to time under an at-the-market Controlled Equity Sales Agreement. The Sales Agreement with Cantor Fitzgerald & Co. permits offers from time to time after effectiveness.
The prospectus discloses that approximately 3.2 million shares have previously been sold for aggregate net proceeds of $87.8 million under an earlier prospectus supplement. The company states proceeds usage is general corporate purposes, including clinical development and manufacturing.
Stoke Therapeutics Chief Patient Officer Jason Hoitt exercised 10,000 restricted stock units into 10,000 shares of common stock. This was a derivative exercise (code M), not an open-market purchase or sale. Following the transaction, he directly owned 13,988 shares of common stock and 30,000 RSUs.
Each RSU converts into one share of common stock upon settlement. The RSU award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service. The reported ownership total also reflects 2,186 shares previously acquired through the company’s employee stock purchase plan.
Stoke Therapeutics Chief Financial Officer Thomas Leggett exercised restricted stock units into common shares in a routine compensation-related transaction. On March 15, 2026, he exercised 14,750 restricted stock units, receiving 14,750 shares of common stock at an exercise price of $0.00 per share.
After the transaction, Leggett directly holds 14,750 shares of common stock and 44,250 restricted stock units. Each RSU represents the right to receive one share of common stock upon settlement, and the award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service with the company.
Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported the vesting and exercise of restricted stock units into common shares. On March 15, 2026, RSU awards covering 33,850 shares of common stock were settled at a price of $0.00 per share.
These RSU awards each represent the right to receive one share of common stock upon settlement and vest in annual 25% installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, subject to continued service. Following these transactions, Ticho directly holds 53,648 shares of Stoke Therapeutics common stock.
Stoke Therapeutics director Edward M. Kaye, MD, increased his direct equity stake through RSU settlements. On March 15, 2026, he exercised or settled restricted stock units covering 61,750 shares of Common Stock at a stated price of $0.00 per share, reflecting equity compensation rather than open‑market purchases.
The RSU awards vest in annual installments of one quarter of the total shares beginning on March 15, 2024 and March 15, 2025, contingent on continued service. Following these transactions, Kaye directly holds 110,874 shares of Stoke Therapeutics Common Stock.